Status:
COMPLETED
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
Lead Sponsor:
St. Jude Children's Research Hospital
Collaborating Sponsors:
Novartis
Conditions:
Tumors
Brain Tumors
Eligibility:
All Genders
3-21 years
Phase:
PHASE1
Brief Summary
Patients with recurrent or refractory solid tumors or brain tumors that are unresponsive to conventional therapy, or with no known effective therapy, will be treated. Experiments in the laboratory hav...
Detailed Description
Although a Phase II portion of this study was planned, it was never initiated.
Eligibility Criteria
Inclusion
- Adequate performance status
- Adequate bone marrow, kidney, heart, and liver function
Exclusion
- Must not be receiving concomitant anti-cancer treatment
- Must not be pregnant
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00187174
Start Date
October 1 2004
End Date
October 1 2008
Last Update
March 4 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105